Benzinga | Jun 18, 2021 06:56AM EDT

JP Morgan Upgrades Crinetics Pharmaceuticals to Overweight, Announces $28 Price Target

JP Morgan analyst Jessica Fye upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Neutral to Overweight and announces $28 price target.